Research programme: MALT1 inhibitors - Centre for Drug Design and Discovery
Latest Information Update: 22 May 2024
At a glance
- Originator Centre for Drug Design and Discovery
- Class Antineoplastics; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies
Most Recent Events
- 15 May 2024 Early research in Haematological malignancies in Belgium (unspecified route) (Centre for Drug Design and Discovery pipeline, May 2024)